ICW Investment Advisors LLC Grows Holdings in Novo Nordisk A/S (NYSE:NVO)

ICW Investment Advisors LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,142 shares of the company’s stock after purchasing an additional 472 shares during the period. Novo Nordisk A/S comprises approximately 1.5% of ICW Investment Advisors LLC’s holdings, making the stock its 15th largest holding. ICW Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,539,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the third quarter worth $28,000. Center for Financial Planning Inc. increased its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Dunhill Financial LLC increased its stake in Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares during the period. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Finally, Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO opened at $76.88 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $344.98 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The business’s 50-day moving average is $83.34 and its two-hundred day moving average is $100.74. Novo Nordisk A/S has a 1 year low of $73.80 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.